| Literature DB >> 29132793 |
J-R Zahar1, S Jolivet2, H Adam3, C Dananché4, J Lizon5, S Alfandari6, H Boulestreau7, N Baghdadi8, J-O Bay9, A-M Bénéteau10, M-E Bougnoux11, M-P Brenier-Pinchart12, J-H Dalle13, S Fournier14, J-G Fuzibet15, C Kauffmann-Lacroix16, I Le Guinche17, D Lepelletier18, N Loukili19, A Lory20, M Morvan21, R Oumedaly22, P Ribaud23, P Rohrlich24, P Vanhems4, S Aho3, D Vanjak25, J-P Gangneux26.
Abstract
The increase use of immunosuppressive treatments in patients with solid cancer and/or inflammatory diseases requires revisiting our practices for the prevention of infectious risk in the care setting. A review of the literature by a multidisciplinary working group at the beginning of 2014 wished to answer the following 4 questions to improve healthcare immunocompromised patients: (I) How can we define immunocompromised patients with high, intermediate and low infectious risk, (II) which air treatment should be recommended for this specific population? (III) What additional precautions should be recommended for immunocompromised patients at risk for infection? (IV) Which global environmental control should be recommended? Based on data from the literature and using the GRADE method, we propose 15 recommendations that could help to reduce the risk of infection in these exposed populations.Entities:
Keywords: Environment; Environnement; Immunocompromised host; Immunodépression; Neutropenia; Neutropénie; Prevention; Prévention
Mesh：
Year: 2017 PMID： 29132793 DOI： 10.1016/j.mycmed.2017.10.004
Source DB: PubMed Journal: J Mycol Med ISSN： 1156-5233 Impact factor: 2.391